The purpose of this study is to see if a drug called sirolimus slows development of lymphangioleiomyomatosis (LAM), a lung disease in which abnormal cells growing inside the lungs prevent them from working properly.
/Image_3097.jpg.aspx)
Sirolimus is approved by the United States Food and Drug Administration (FDA) for the treatment of LAM. A recent trial showed that sirolimus stabilized lung function in patients with moderate and severe disease. Our researchers want to find out if giving low-dose sirolimus earlier in the course of treatment safely and effectively prevents further lung damage from LAM.